11 Best Performing NASDAQ Stocks So Far in 2025

2. Palvella Therapeutics Inc. (NASDAQ:PVLA)

Number of Hedge Fund Holders: 9

Average Upside Potential as of March 31: 136.33%

Palvella Therapeutics Inc. (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapies to treat patients with serious and rare genetic skin diseases. Its lead product candidate QTORIN rapamycin is in a Phase 3 clinical trial for the treatment of microcystic lymphatic malformations.

The Phase 3 clinical trial is called SELVA and has around 40 participants, which also include children between the ages of 3 and 5. Positive results from the earlier held Phase 2 trial have shown 100% of participants showing improvements. Results from the SELVA trial are expected in Q1 2026. It has received a grant of up to $2.6 million from the FDA.

QTORIN rapamycin is essentially a topical gel that targets the underlying pathway of Microcystic LMs. This disease affects around 30,000 people in the US alone, with no primary approved treatment in the market. Palvella Therapeutics Inc. (NASDAQ:PVLA) aims to be the first company to provide an approved therapy for patients suffering from Microcystic LMs.